press releases

  1. Tanner Pharma Group and ExeGi Pharma Announce Partnership to Distribute High Potency Probiotic in Mexico to Support Patients with Gut Microbiome Imbalance

    Rockville, M.D., and Charlotte, N.C., April 12, 2023 – ExeGi Pharma LLC (“ExeGi”), a leading developer of live biotherapeutic drugs and probiotics, has announced a partnership with TannerLAC, Inc. (“TannerLAC”), a division of Tanner Pharma Group, to distribute Visbiome® in Mexico. Visbiome® is a high-potency probiotic medical food that helps manage dysbiosis associated with medical…

    Read More
  2. Tanner Pharma Group to Distribute an Innovative Product that Protects and Repairs the Gastrointestinal Mucosa

    Teramo (Italy) and Charlotte, N.C. (USA), on April 3, 2023 – Azienda Farmaceutica Italiana (“AFI”), an Italian pharmaceutical company and innovator in therapeutic solutions and new treatment possibilities, and TannerLAC, Inc. (“TannerLAC”), a division of Tanner Pharma Group, have entered into a license agreement for the distribution of Hepilor® in Latin America. Hepilor® is a…

    Read More
  3. Epimune and Tanner Pharma Group Enter Into Distribution Partnership for Latin America

    Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro diagnostic test in the…

    Read More
  4. Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar)

    SALT LAKE CITY and CHARLOTTE, N.C., Dec. 1, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, announced today that they have launched a global…

    Read More
  5. Sending Wilson home: A story of perseverance and teamwork

    (Repost from ZNM) Wilson – a small child with a rare muscle condition called centronuclear myopathy – gets life-saving medical equipment and goes home to his family after spending almost 2 years at the hospital thanks to the support of two patient organizations in Europe and US and the financial assistance and guidance from Tanner…

    Read More
  6. Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®

    Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®   MILAN, ITALY and CHARLOTTE, USA – Dompé farmaceutici S.p.A. (“Dompé”) and Tanner Pharma Group, Inc. today announced they have entered into an agreement whereby Tanner Pharma Group will become Dompé’s exclusive distribution partner for Oxervate (cenegermin) in selected countries. The agreement names Tanner Pharma…

    Read More
  7. Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea® (micellular paclitaxel)

    SALT LAKE CITY and CHARLOTTE, N.C., July 27, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, today announced a partnership that will facilitate access to Apealea® (micellular paclitaxel) on a named…

    Read More
  8. Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

    Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc. May 12, 2020 For Immediate Release Contact: Telephone: 704-552-8407 Email: versacloz@tannerpharma.com   CHARLOTTE, N.C. – Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Tasman Pharma Inc. The agreement names Tanner as a…

    Read More
  9. Tanner Pharma Group Initiates Named Patient Program for XIAFLEX®

    CHARLOTTE, NC –Tanner Pharma Group, Inc. today announced they have partnered with Endo Pharmaceuticals, Inc. to initiate a multi-year Named Patient Program for XIAFLEX® (collagenase clostridium histolyticum), an important nonsurgical treatment option for patients with Dupuytren’s contracture and Peyronie’s disease. XIAPEX®, also owned by Endo, was previously marketed by Swedish Orphan Biovitrum AB (Sobi) in…

    Read More
  10. Tanner Pharma Group to Attend CTS Europe, DCAT, PharmagoraPlus, PQMD, and GCSG US Conferences

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com CHARLOTTE, N.C. – Key directors from Tanner Pharma Group (“Tanner Pharma”), a Charlotte-based global pharmaceutical services company, will attend several international healthcare conferences throughout the upcoming months of March and April. The team will join other global executives for the following events:  Clinical…

    Read More
  11. PQMD Welcomes Tanner Pharma Group to Membership

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com Annapolis, Md. – January 23, 2019 – The Partnership for Quality Medical Donations (PQMD), is proud to announce the addition of Tanner Pharma Group to their membership. The Charlotte, N.C., based global pharmaceutical company becomes the 42nd member of PQMD. “Tanner Pharma Group is proud…

    Read More
  12. Tanner Pharma Group Signs Distribution Agreement with Nephcentric LLC

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com CHARLOTTE, N.C. – Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Nephcentric LLC (“Nephcentric”), a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders.…

    Read More
  13. Tanner Pharma Group Signs Distribution Agreement with MannKind Corporation

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com CHARLOTTE, N.C. – Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with MannKind Corporation (“MannKind”, NASDAQ: MNKD), a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes…

    Read More
  14. Tanner Pharma Group Delivers on “Last Mile” in Global Health

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 lstevens@tannerpharma.com SEATTLE, WA – The Max Foundation (“Max”), an international health organization dedicated to serving cancer patients, and Tanner Pharma Group (“Tanner”), a global pharma services company specializing in access to critical medication, are committed partners in bringing thousands of patients around the globe daily…

    Read More
  15. Tanner Pharma Group to Present at Bourne Partners 5th Annual Global Healthcare Executive Summit

    Joshua Cooper to Moderate Healthcare Services Panel, “Changing Dynamics of Pharma Services”   CHARLOTTE, N.C., August 21, 2015 – Tanner Pharma Group will be largely showcased at the upcoming Bourne Partners Fifth Annual Global Healthcare Executive Summit on September 3, in Charlotte, North Carolina. The conference, held at the internationally renowned Mint Museum, will feature…

    Read More
  16. Tanner Pharma Group Executives to Present at 2015 BIO International

    Presentations to Focus on Enhancing Access and Commercial Success in Challenging International Markets with Minimal Risk and Investment CHARLOTTE, N.C. – Top executives from Tanner Pharma Group will speak at the largest life-science conference in the world, the 2015 BIO International Convention, scheduled for June 15-18 in Philadelphia. The presentations will provide key insights into…

    Read More
  17. Tanner Pharma Group Signs Exclusive Distribution Agreement with Merz North America for Named Patient Sales of Cuvposa® (glycopyrrolate) oral solution into Emerging Markets

    New access for children in Latin American markets with neurologic conditions that cause chronic severe drooling Tanner Pharma Group, a global provider of integrated specialty access solutions, announces the signing of an exclusive distribution agreement with Merz North America, a specialty healthcare company with a strong commitment to the U.S. neurosciences space. The agreement names…

    Read More

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.